<SEC-DOCUMENT>0001654954-18-000397.txt : 20180116
<SEC-HEADER>0001654954-18-000397.hdr.sgml : 20180116
<ACCEPTANCE-DATETIME>20180116120642
ACCESSION NUMBER:		0001654954-18-000397
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180112
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180116
DATE AS OF CHANGE:		20180116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		18527966

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cvm_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">UNITED
STATES</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SECURITIES
AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">WASHINGTON, D.C.
20549</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">FORM
8-K</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">CURRENT
REPORT</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant to Section
13 or 15(d) of the</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Securities Exchange
Act of 1934</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Date of
Report (date of earliest event reported): January 12,
2018</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI CORPORATION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">(Exact
name of Registrant as specified in its charter)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 20%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Colorado</font></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 20%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">001-11889</font></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 20%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">84-0916344</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 20%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(State
or other jurisdiction of incorporation)</font></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 20%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Commission
File No.)</font></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 20%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(IRS
Employer Identification No.)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">8229
Boone Boulevard, Suite 802</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Vienna, Virginia 22182</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;(Address
of principal executive offices, including Zip Code)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Registrant&#x2019;s
telephone number, including area code:&#xA0;&#xA0;&#xA0;
<font style="text-decoration: underline">(703)
506-9460</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
N/A</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Former
name or former address if changed since last report)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: rgb(255, 255, 255);">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
3.03.&#xA0;&#xA0;&#xA0; Material Modification to Rights of Security
Holders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
January 12, 2018 the exercise price of the Company&#x2019;s
outstanding Series S warrants (CUSIP number 150837177), that are
publicly traded under the symbol &#x201C;CVM WS&#x201D; on the NYSE
American, was changed to $3.00 per share for a three month period
which will end on April 12, 2018. After this date, the exercise
price will revert back to $31.25 per share of common stock. As a
result of the reverse stock split which became effective on the
NYSE American on June 15, 2017, 25 Series S warrants are required
to purchase one share of common stock. The Series S warrants expire
on October 11, 2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company issued a press release, filed as Exhibit 99, announcing the
repricing of the exercise price of the Series S
warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
9.01.&#xA0;&#xA0;&#xA0; Financial Statements and
Exhibits.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 12%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold"><font style="font-weight: bold"><font style="font-family: Times New Roman; font-size: 13px; font-weight: bold;">
Exhibit</font></font></font></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div><font style="font-weight: bold"><font style="font-weight: bold"><font style="font-family: Times New Roman; font-size: 13px; font-weight: bold;">
&#xA0;</font></font></font></div>
</td>
<td style="vertical-align: top; width: 87%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold"><font style="font-weight: bold"><font style="font-family: Times New Roman; font-size: 13px; font-weight: bold;">
Description</font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 87%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="cvm_ex991.htm"><font style="font-family: Times New Roman; font-size: 13px">99</font></a></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 87%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Press
Release dated January 16, 2018</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;margin-left:0px;">
<tr style="">
<td rowspan="1" style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 38%;">
<div><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">CEL-SCI
CORPORATION</font></div>
</td>
<td rowspan="1" style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: top; width: 50%; border-bottom: medium solid rgb(255, 255, 255);">
<font style="font-family: Times New Roman; font-size: 13px">Date:
January 16, 2018</font></td>
<td style="vertical-align: top; width: 3%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid black; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/&#xA0;
<font style="font-family: Times New Roman; font-size: 13px">Patricia
Prichep</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; white-space: nowrap;">
<font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px">Patricia
Prichep</font></font></td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px">Senior Vice
President of Operations</font></font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<br>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">3</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cvm_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
</div>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Exhibit 99.1</font></font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0 auto;width: 100%;">
<tr>
<td style="width: 50%">
<div><font>&#xA0;</font>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="cvm_ex991000.jpg"></div>
</div>
</td>
<td style="width: 50%; vertical-align: bottom;">
<div><font>&#xA0;</font>
<div style="text-align: right; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 24px"><font style="color: #7F7F7F">
N</font><font style="font-variant: small-caps; color: #7F7F7F">EWS
RELEASE</font></font></div>
</div>
</td>
</tr></table>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: auto; margin-right: auto; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--line--><br></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;<br>
</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 47%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">8229
Boone Boulevard, Suite 802</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Vienna,
VA 22182. USA</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Telephone
(703) 506-9460</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">www.cel-sci.com</font></div>
</td>
<td style="vertical-align: top; width: 53%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">COMPANY
CONTACT:</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 192px">
<font style="font-family: Times New Roman; font-size: 13px">Gavin
de Windt</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 192px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
Corporation</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 192px">
<font style="font-family: Times New Roman; font-size: 13px">(703)
506-9460</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI ANNOUNCES ADJUSTMENT TO WARRANT EXERCISE PRICE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Vienna, VA, January 16, 2018</font> &#x2013; CEL-SCI Corporation
<font style="font-weight: bold">(NYSE American: CVM)</font>
announced today that the outstanding Series S warrants (CUSIP
number 150837177) that are publicly traded under the symbol
&#x201C;CVM WS&#x201D; on the NYSE American have been repriced to
$3.00 per share of common stock for a three month period which will
end on April 12, 2018. After this date, the exercise price will
revert back to $31.25 per share of common stock. As a result of the
reverse stock split which became effective on the NYSE American on
June 15, 2017, 25 warrants are required to purchase one share of
common stock. The warrants expire on October 11, 2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
About CEL-SCI Corporation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
is a Phase 3 cancer immunotherapy company. When it comes to cancer
immunotherapy, CEL-SCI believes it is most logical to boost the
patient&#x2019;s immune system while it is still intact in order to
have the greatest possible impact on survival. Therefore, CEL-SCI
treats patients who are newly diagnosed with head and neck cancer
with its lead investigational immunotherapy Multikine* (Leukocyte
Interleukin, Injection), BEFORE they have received surgery,
radiation and/or chemotherapy, at a time when the immune system
should be at its strongest. This approach is unique. Most other
cancer immunotherapies are used only after conventional therapies
have been tried and/or failed. Head and neck cancer represents
about 6% of all cancers. Multikine has received Orphan Drug
designation from the FDA for the treatment of head and neck cancer
patients with advanced squamous cell carcinoma.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #181818">
The Company&#x2019;s LEAPS technology is being developed as a
potential therapeutic vaccine for rheumatoid arthritis and is
supported by a grant from the</font> National Institute of
Arthritis and Musculoskeletal and Skin Diseases of the <font style="color: #181818">National Institutes of Health. The Company has
operations in Vienna, Virginia, and in/near Baltimore,
Maryland.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Forward-Looking Statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">This
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
When used in this press release, the words "intends," "believes,"
"anticipated," "plans" and "expects," and similar expressions, are
intended to identify forward-looking statements. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Factors that
could cause or contribute to such differences include, an inability
to duplicate the clinical results demonstrated in clinical studies,
timely development of any potential products that can be shown to
be safe and effective, receiving necessary regulatory approvals,
difficulties in manufacturing any of the Company's potential
products, inability to raise the necessary capital and the risk
factors set forth from time to time in CEL-SCI&#x2019;s filings with
the Securities and Exchange Commission, including but not limited
to its report on Form 10-K for the year ended September 30, 2017.
The Company undertakes no obligation to publicly release the result
of any revision to these forward-looking statements which may be
made to reflect the events or circumstances after the date hereof
or to reflect the occurrence of unanticipated events.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; font-size: 13px">
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in
progress.</font><br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cvm_ex991000.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cvm_ex991000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !H -L# 2(  A$! Q$!_\0
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M44 94FCM+8S1RRJUQ-,L[-@A=P(P, YQA0.N>](NDO\ V==P8ACDN.Z;B!T
MR2<GI[5K44 96HZ4UU=BXC\MF,7E,LA8#&<@_*>>IXJQ'8F.ZBD5E"1VWD!0
M,=QS].*NT4 9+Z5+_9]G;KY+O;IMWL60@XQE67D?3O27.DRS?993(DT\4)B<
MR%E#9Q\WR]\BM>B@#*N-+=K2VA@6 -"FU6&Y"AQU4@Y ]JTH4>."-))#(ZJ
MSD8W''6GT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
